Drug, device, biologic, or combination product: how FDA classifies your product and who decides

Before a sponsor can pick a marketing pathway, write a development plan, or even settle on a cGMP framework, one threshold question has to be answered: what kind of medical product is this in the eyes of the FDA? The answer is not a matter of marketing preference. It is driven by statutory definitions, a specific regulation on how to assign products that span more than one category, and a designated FDA office with delegated authority to make the call. This article walks through the legal definitions, the combination-product framework, the primary mode of action test, and the formal mechanisms FDA uses to decide and to tell you the answer.

The three statutory buckets

Classification starts with definitions written into statute, not regulation or guidance. Three of them do the work.

Drug, under section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), means articles recognized in the official USP, Homeopathic Pharmacopoeia, or National Formulary; articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease; articles (other than food) intended to affect the structure or any function of the body; and articles intended for use as a component of any of the foregoing ¹.

Device, under section 201(h) of the FD&C Act, means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or similar article, including any component, part, or accessory, that is recognized in the NF or USP, is intended for diagnosis or for the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or any function of the body, and which does not achieve its primary intended purposes through chemical action within or on the body and is not dependent upon being metabolized for the achievement of its primary intended purposes ¹². That final clause is the operative dividing line between a device and a drug: the mechanism, not the format, is what matters. A physical or mechanical mode of action points to a device; a chemical or metabolic one points to a drug.

Biological product, under section 351(i) of the Public Health Service (PHS) Act, means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine (or its derivatives), applicable to the prevention, treatment, or cure of a disease or condition of human beings ¹. Note the overlap: a biological product also meets the drug definition. Biologics are, in effect, a specialized subset regulated under the PHS Act licensure scheme rather than the FD&C Act new-drug scheme, which is why they are handled as their own category for jurisdictional purposes.

These definitions are administered by three review centers: the Center for Drug Evaluation and Research (CDER) for drugs, the Center for Biologics Evaluation and Research (CBER) for biologics, and the Center for Devices and Radiological Health (CDRH) for devices.

When a product is more than one thing: combination products

Many modern products do not sit cleanly in a single bucket. A prefilled autoinjector is a drug plus a delivery device. A drug-eluting stent is a device plus a drug. An antibody conjugated to a cytotoxic payload blends biologic and drug attributes. FDA handles these as combination products, defined at 21 CFR 3.2(e), which groups them into three practical categories ³⁶⁷:

• Single-entity (physically or chemically combined). Two or more constituents are combined into one integrated product. Examples: a prefilled syringe, a transdermal patch, a metered-dose inhaler, a prefilled drug-delivery device, and an antibody-drug conjugate ⁴⁶⁷. A drug-eluting stent is a frequently cited example of an integrated device-drug combination ⁸.
• Co-packaged. Distinct constituent parts are packaged together in a single package or kit. Examples: a drug vial packaged with a delivery syringe, a drug packaged with a diluent and a reconstitution or transfer device, or a surgical or first-aid kit ⁴⁶⁷.
• Cross-labeled (separately packaged). Constituents are sold separately but are labeled for use together and are needed to achieve the intended effect. The classic example is a photosensitizing drug used with a specific light source or laser ⁵⁶.

Being a combination product does not change what the constituents are; it changes how FDA decides which center leads the review and which set of application and quality-system requirements applies. The statutory hook for all of this is section 503(g) of the FD&C Act ³.

The deciding test: primary mode of action (PMOA)

For a combination product, FDA assigns a single lead center for premarket review and primary oversight, and the assignment turns on the product's primary mode of action. Under the combination-product rule, "mode of action" is the way a product acts to achieve its intended therapeutic effect, and the PMOA is "the single mode of action of a combination product that provides the most important therapeutic action" ⁶.

The assignment logic runs as follows ⁶⁹¹⁰:

• If the PMOA is that of a drug, the lead center is CDER.
• If the PMOA is that of a biological product, the lead center is CBER (or the component responsible for that biologic).
• If the PMOA is that of a device, the lead center is CDRH.

So a prefilled autoinjector whose therapeutic work is done by the drug is led by CDER even though it contains a device constituent; a drug-eluting stent whose primary action is mechanical scaffolding of the vessel has historically been treated as device-led ⁸¹¹.

What if the PMOA cannot be determined with reasonable certainty? The rule at 21 CFR 3.4 supplies a two-step algorithm ⁶:

1. Consistency. Assign the product to the center that regulates other combination products presenting similar questions of safety and effectiveness.
2. Expertise. If the consistency step does not resolve the assignment, assign the product to the center with the most expertise related to the most significant safety and effectiveness questions the product raises.

In practice, FDA also publishes intercenter agreements and jurisdictional updates that codify how recurring product types are handled, so that similar products are assigned consistently rather than case by case ¹¹¹².

Who at FDA actually decides

The decision-maker is the Office of Combination Products (OCP). OCP is FDA's designated point of contact for combination-product and jurisdictional questions. It classifies products as drugs, devices, biological products, or combination products; assigns each product to a lead center for premarket review and postmarket oversight; and coordinates reviews that span more than one center ⁹⁵.

OCP was established on December 24, 2002, pursuant to the Medical Device User Fee and Modernization Act of 2002 (MDUFMA), which was enacted on October 26, 2002 and which added the combination-product provisions now codified at section 503(g) of the FD&C Act ³¹⁷. The authority to make a formal classification and assignment determination is delegated to the Director of OCP, the Product Assignment Officer, and the Product Classification Officer, and that authority may not be further redelegated ¹⁴.

The formal mechanisms: RFD and Pre-RFD

There are two routes to get FDA's view, one informal and one binding.

Pre-RFD is an informal, non-binding process. A sponsor submits a description of the product and its own analysis, and OCP provides a preliminary assessment of the product's regulatory identity (drug, device, biologic, or combination product) and likely lead center ¹³. It is a lower-burden way to test a classification theory or de-risk a development plan before committing to a formal request.

Request for Designation (RFD) is the formal, regulated process under 21 CFR Part 3. The sponsor files an RFD stating the product, its constituents, and its recommended classification and center assignment. FDA must issue a letter of designation within 60 days of filing ¹⁶. The letter is FDA's written determination of the product's classification and lead center. Two features give the RFD real teeth ¹⁶:

• Default to the sponsor's recommendation. If FDA does not issue a letter of designation within the 60-day window, the classification and assignment the sponsor recommended in the RFD become the designation by operation of the rule.
• Limited ability to change it later. Once made, the designation may be changed only with the written consent of the sponsor, or when FDA determines that a change is necessary to protect the public health.

OCP posts redacted RFD decision letters, which are a useful precedent library when arguing an analogous product's classification ¹⁵.

Why the classification drives everything downstream

The classification is not an academic label. It cascades into the entire regulatory strategy:

• Marketing application. The lead center and the nature of the constituents determine the application type, an NDA (or ANDA) for a drug, a BLA for a biologic, or a PMA, 510(k), or De Novo for a device. A combination product is generally reviewed through a single lead center under the application type tied to its PMOA, rather than through multiple parallel applications, though FDA may consult the other center on the secondary constituent ⁶⁸.
• Quality systems and cGMP. Combination products are subject to the streamlined cGMP framework at 21 CFR Part 4, which lets a manufacturer operate under either the drug cGMPs or the device quality system regulation while incorporating the specified provisions of the other. FDA's Quality Management System Regulation update, which aligns 21 CFR Part 820 with ISO 13485:2016, included conforming edits to Part 4 to clarify the device quality-system expectations for combination products ¹⁸¹⁹.
• Postmarket obligations. Adverse-event and safety reporting for combination products follow the Part 4 postmarketing safety reporting regime, which blends the drug, device, and biologic reporting requirements according to the constituents present ¹⁸.

Because of this cascade, the classification question is worth resolving early and, where there is any genuine ambiguity, worth resolving formally. A wrong assumption about whether a product is a drug, a device, or a device-led combination can invalidate an entire development plan, from the pivotal-study design to the manufacturing quality system.

Practical takeaways for regulatory teams

• Start from the section 201(h) mechanism test. If the product's primary intended purpose is achieved by chemical action or depends on being metabolized, it is on the drug/biologic side; if the primary effect is physical or mechanical, it points to device ¹².
• If the product combines constituents, identify the primary mode of action first, because that single determination drives the lead center, the application type, and the cGMP framework ⁶.
• Use a Pre-RFD to pressure-test a classification theory informally, and reserve the RFD for when you need a binding designation, remembering the 60-day clock and the default-to-sponsor rule that comes with it ¹³¹⁶.
• Mine OCP's published intercenter agreements, jurisdictional updates, and redacted RFD decision letters for precedent on analogous products before you file ¹¹¹²¹⁵.